Baloxavir

Aethlon Medical, Inc. discusses its Hemopurifier device, designed to remove enveloped viruses like H5N1 from blood, with a study showing 99% removal in vitro. The device has been used in 38 patients for diseases like hepatitis C, HIV, COVID-19, and Ebola, and holds FDA Breakthrough Device designation for life-threatening viruses. Aethlon monitors Bird Flu cases and potential treatment needs.

NanoViricides reported Q3 2024 financials with $3.87M cash and $7.36M net property assets. Lead drug NV-387, a broad-spectrum antiviral, is advancing to Phase II trials for MPOX, RSV, Influenza, and COVID. A Phase Ia/Ib trial was completed with no adverse events. The company raised $1.71M through an ATM offering and has a $3M credit line, but additional funding is needed for planned Phase II trials. NV-387 showed promising results in animal trials, potentially offering superior effectiveness over existing treatments.

NanoViricides, Inc. reported its FY2024 financials, highlighting a cash balance of $4.97M, P&E assets of $7.5M, and current liabilities of $1.36M. The company raised $3.12M through an ATM offering and has $9.5M available for operations. Despite this, substantial doubt exists about its ability to fund planned objectives, including a Phase II trial for NV-387. NV-387, a broad-spectrum antiviral, showed potential in treating RSV, COVID, Influenza, and MPOX, with plans to advance it into Phase II trials.